Functional Genomics of Solid Tumors (FUNGEST)

Director : 

Jessica Zucman-Rossi

Deputy Director : 

Didier Jean

 

We develop translational genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis (e.g. new genomic alterations, clinical/genomic risk factors) and to propose biomarkers and therapeutic targets that could be introduced in clinical practice. Our general strategy is based on the large-scale genomic analysis of large cohorts of patients with liver tumors (benign and malignant), mesothelioma and renal cancer. The team is organized in 4 groups with their projects:

Scientific Themes

Functional Genomics of Liver and Renal Tumors

Focused on the characterization and functional validation of genomic alterations in benign and malignant liver tumors, identification of new clinical/genomic risk factors, and ultimately, translation to the clinics.

Computational Cancer Genome Analysis

Develops innovative strategies for integrative genomic data analysis in order to decipher the interaction between clinical risk factors, endogenous cellular processes and genomic alterations in liver carcinogenesis.

Therapeutic Targets in liver tumors

Develops an integrated approach that extends from the study of the molecular basis of tumor initiation and progression to applications of targeted treatment and the identification of biomarkers predicting the therapeutic response.

Functional Genomics of Mesothelioma

studies pathogenesis of malignant pleural mesothelioma (MPM), a rare tumor, with poor prognosis due to the lack of efficient treatment.


Main publications

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo.G, Tubacher E, Bacq B, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2019 in press.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology. 2018 Aug;155(2):431-442.e10

Calderaro J, Letouzé E, Bayard Q, Boulai A, Renault V, Deleuze JF, Bestard O, Franco D, Zafrani ES, Nault JC, Moutschen M, Zucman-Rossi J*. Systemic AA amyloidosis cased by inflammatory hepatocellular adenoma. The New England Journal of Medicine. 2018, 379(12):1178-1180.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018 Jul;68(1):103-112.

Letouzé E*, Shinde J*, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications 2017 Nov 3;8(1):1315. *equally contributed

 

All publications

Fundings